1. Home
  2. PEB vs DFTX Comparison

PEB vs DFTX Comparison

Compare PEB & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pebblebrook Hotel Trust of Beneficial Interest

PEB

Pebblebrook Hotel Trust of Beneficial Interest

HOLD

Current Price

$14.11

Market Cap

1.5B

Sector

Real Estate

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$23.29

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PEB
DFTX
Founded
2009
N/A
Country
United States
United States
Employees
60
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PEB
DFTX
Price
$14.11
$23.29
Analyst Decision
Hold
Strong Buy
Analyst Count
11
7
Target Price
$12.59
$39.71
AVG Volume (30 Days)
2.4M
1.7M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
0.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.56
$14.62
52 Week High
$14.23
$23.41

Technical Indicators

Market Signals
Indicator
PEB
DFTX
Relative Strength Index (RSI) 69.45 74.64
Support Level $10.21 $16.37
Resistance Level N/A N/A
Average True Range (ATR) 0.34 1.31
MACD 0.11 0.22
Stochastic Oscillator 96.00 64.88

Price Performance

Historical Comparison
PEB
DFTX

About PEB Pebblebrook Hotel Trust of Beneficial Interest

Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: